Lilly Narrows GLP-1 Revenue Gap with Novo Nordisk

Eli Lilly has reported strong Q2 results, narrowing the gap with Novo Nordisk in revenue from GLP-1 drugs for obesity and diabetes. With revenues exceeding expectations, Mounjaro, Lilly’s type 2 diabetes treatment, generated $3.091 billion and the obesity drug Zepbound made $1.243 billion. The results boosted Lilly’s stock, and analysts have raised their worldwide sales forecast for Mounjaro and Zepbound. Meanwhile, Novo Nordisk reported strong sales growth but failed to meet some estimates due to intensifying competition and supply chain issues.